Structure Therapeutics Inc. (GPCR) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.59
↓-38% vs avg
5yr avg: 2.56
30Y Low1.7·High3.3
ROE
↑
-11.9%
↓+57% vs avg
5yr avg: -27.8%
30Y Low-53%·High-12%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GPCR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Structure Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $2.4B | $4.1B | $1.4B | $1.5B | — | — | — |
| Enterprise Value | $1.6B | $3.3B | $1.3B | $1.4B | — | — | — |
| P/E Ratio → | -17.02 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 1.59 | 2.72 | 1.65 | 3.31 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GPCR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
GPCR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -11.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -11.9% | -11.9% | -18.6% | -53.1% | — | — | — |
| ROA | -11.4% | -11.4% | -17.7% | -30.9% | -49.1% | -53.4% | -41.1% |
| ROIC | -30.3% | -30.3% | -23.1% | -82.2% | — | — | — |
| ROCE | -24.1% | -24.1% | -23.9% | -37.9% | -56.1% | -54.6% | -44.7% |
GPCR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $800M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.52 | -0.19 | -0.27 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -7.67 | — | -308.58 | — |
Net cash position: cash ($800M) exceeds total debt ($6M)
GPCR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Structure Therapeutics Inc.'s current ratio of 24.81x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 19.14x to 24.81x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 24.81 | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Quick Ratio | 24.81 | 24.81 | 24.74 | 19.14 | 7.16 | 12.62 | 12.64 |
| Cash Ratio | 22.85 | 22.85 | 24.53 | 18.89 | 6.98 | 12.39 | 12.32 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
GPCR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Structure Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $59M | $53M | $37M | $37M | $37M | $37M |
Peer Comparison
Compare GPCR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GPCRYou | $2B | -17.0 | — | — | — | — | -11.9% | -30.3% | — |
 CHRS | $212M | 1.2 | — | — | -37.3% | -429.5% | 275.4% | — | — |
 RVMD | $32B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARWR | $11B | -6486.9 | 91.8 | 70.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 CGEM | $903M | -4.0 | — | — | — | — | -44.0% | -43.5% | — |
 VKTX | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
 PEPG | $127M | -0.9 | — | — | — | — | -67.4% | -73.2% | — |
 NVO | $203B | 12.6 | 9.3 | 44.6 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 LLY | $933B | 43.0 | 31.0 | 104.0 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 TERN | $5B | -47.3 | — | — | — | — | -29.6% | -42.2% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See GPCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GPCR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GPCR vs CHRS
Side-by-side business, growth, and profitability comparison vs Coherus Oncology, Inc..
Start ComparisonGPCR — Frequently Asked Questions
Quick answers to the most common questions about buying GPCR stock.
What is Structure Therapeutics Inc.'s P/E ratio?
Structure Therapeutics Inc.'s current P/E ratio is -17.0x. This places it at the 50th percentile of its historical range.
What is Structure Therapeutics Inc.'s ROE?
Structure Therapeutics Inc.'s return on equity (ROE) is -11.9%. The historical average is -27.8%.
Is GPCR stock overvalued?
Based on historical data, Structure Therapeutics Inc. is trading at a P/E of -17.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.